108 related articles for article (PubMed ID: 3175990)
1. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action.
Ushiyama S; Ito T; Asai F; Oshima T; Terada A; Matsuda K; Yamazaki M
Thromb Res; 1988 Sep; 51(5):507-20. PubMed ID: 3175990
[TBL] [Abstract][Full Text] [Related]
2. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
Terashita Z; Imura Y; Tanabe M; Kawazoe K; Nishikawa K; Kato K; Terao S
Thromb Res; 1986 Jan; 41(2):223-37. PubMed ID: 3083523
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046).
Hiraku S; Taniguchi K; Wakitani K; Omawari N; Kira H; Miyamoto T; Okegawa T; Kawasaki A; Ujiie A
Jpn J Pharmacol; 1986 Jul; 41(3):393-401. PubMed ID: 3093741
[TBL] [Abstract][Full Text] [Related]
4. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function.
Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y
Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191
[TBL] [Abstract][Full Text] [Related]
5. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben.
Olson RW; Cohen DS; Ku EC; Kimble EF; Renfroe HB; Smith EF
Eur J Pharmacol; 1987 Jan; 133(3):265-73. PubMed ID: 3104066
[TBL] [Abstract][Full Text] [Related]
6. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate.
Asai F; Ito T; Ushiyama S; Matsuda K; Oshima T
Arzneimittelforschung; 1991 May; 41(5):506-10. PubMed ID: 1898421
[TBL] [Abstract][Full Text] [Related]
7. RS-5186, a novel, long-acting thromboxane synthetase inhibitor.
Matsuda K; Ushiyama S; Ito T; Asai F; Oshima T; Ikeda T; Nakagawa A; Terada A; Yamazaki M
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():674-7. PubMed ID: 2526559
[No Abstract] [Full Text] [Related]
8. Irreversible inhibition of thromboxane (TX) A2 synthesis by Y-20811, a selective TX synthetase inhibitor.
Mikashima H; Ochi H; Muramoto Y; Hirotsu K; Arima N
Biochem Pharmacol; 1992 Jan; 43(2):295-9. PubMed ID: 1739418
[TBL] [Abstract][Full Text] [Related]
9. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
[TBL] [Abstract][Full Text] [Related]
10. Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death.
Edmonds LC; Lefer AM
Life Sci; 1984 Oct; 35(17):1763-8. PubMed ID: 6434893
[TBL] [Abstract][Full Text] [Related]
11. A novel pyridobenzazepinone derivative with long lasting thromboxane synthase inhibition.
Miki I; Kishibayashi N; Takeda M; Suzuki K; Obase H; Ishii A
Arzneimittelforschung; 1995 Oct; 45(10):1066-70. PubMed ID: 8595060
[TBL] [Abstract][Full Text] [Related]
12. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet thromboxane synthetase by 1-(3-benzyloxy-1[E]octenyl)imidazole.
Sincholle D; Coquelet C; Bonne C
Arzneimittelforschung; 1986; 36(1):117-9. PubMed ID: 3082339
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion by 2-phenylaminoadenosine (CV-1808) in anesthetized dogs.
Tanabe M; Terashita Z; Nishikawa K; Hirata M
J Cardiovasc Pharmacol; 1984; 6(3):442-8. PubMed ID: 6202970
[TBL] [Abstract][Full Text] [Related]
15. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
16. Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. Effects on renal hemodynamics.
Lianos EA; Andres GA; Dunn MJ
J Clin Invest; 1983 Oct; 72(4):1439-48. PubMed ID: 6685136
[TBL] [Abstract][Full Text] [Related]
17. Myocardial salvage by a novel thromboxane A2 synthetase inhibitor in a canine coronary occlusion-reperfusion model.
Toki Y; Hieda N; Okumura K; Hashimoto H; Ito T; Ogawa K; Satake T
Arzneimittelforschung; 1988 Feb; 38(2):224-7. PubMed ID: 3370068
[TBL] [Abstract][Full Text] [Related]
18. [Beneficial effect of a selective TXA2 synthetase inhibitor, OKY-046, both on thromboxane B2 production and vascular damage after spinal cord injury in rat spinal cord].
Morimoto K; Ikata T; Tounai T
Nihon Seikeigeka Gakkai Zasshi; 1990 Jan; 64(1):82-8. PubMed ID: 2319197
[TBL] [Abstract][Full Text] [Related]
19. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
[TBL] [Abstract][Full Text] [Related]
20. 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
Martinez GR; Walker KA; Hirschfeld DR; Bruno JJ; Yang DS; Maloney PJ
J Med Chem; 1992 Feb; 35(4):620-8. PubMed ID: 1311763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
